Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)

Completed · Phase 3 · Has a placebo group

Conditions studied: Perennial Allergic Rhinitis

In brief

The purpose of the study is to evaluate the effects of BDP HFA Nasal Aerosol on HPA-axis function.

Key facts

Study ID

NCT01133626

Run by

Teva Branded Pharmaceutical Products R&D, Inc.

People needed

107

Starts

2010-06-01

Expected to finish

2010-09-01

Last updated by the study team

2012-07-04

Who can join

Age: 12 and older, up to 45. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Informed Consent
• Male or female subjects 12-45 years of age
• Documented history of perennial allergic rhinitis
• General good health
• Other criteria apply

You may not qualify if…

• History of physical findings of nasal pathology (within 60 days prior to Screening Visit 1)
• Participation in any investigational drug study 30 days preceding Screening Visit 1
• History of respiratory infection/disorder with 14 days preceding Screening Visit 1
• Use of any prohibited concomitant medications

Where it is running

• Teva Clinical Study Site — North Dartmouth, Massachusetts, United States
• Teva Clinical Study Site — New Braunfels, Texas, United States
• Teva Clinical Study Site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.